1 recruiting, 1 terminated, 1 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Unknown 1 |
Follow Quanli Gao: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC L-TIL, Tislelizumab, Docetaxel - Non-small Cell Lung Cancer | Phase 2 | Unknown | Quanli Gao | 33 | 2022-09-16 | 2024-05-23 |
| L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma Tislelizumab - Malignant Melanoma | Phase 2 | Terminated | Quanli Gao | 9 | 2021-07-01 | 2024-07-03 |
| The Immune Assessment of PD-1 Antibody Therapy in Tumor PD-1 Inhibitors - Efficacy, Team, Adverse Event | Recruiting | Quanli Gao | 3000 | 2021-07-01 | 2024-11-18 |
Carcinoma, Non-Small-Cell Lung (1) · Melanoma (1)
tislelizumab (2) · Docetaxel (1) · Immune Checkpoint Inhibitors (1) · Nivolumab (1) · pembrolizumab (1)
China (3)